Luminita Mihalcean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luminita Mihalcean has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Mihaela Burac
Department of Obstetrics, Gynecology and Human Reproduction, “Nicolae Testemițanu” State University of Medicine and Pharmacy, MD-2004 Chișinău, Moldova
3 shared publications - Hristiana Capros
Nicolae Testemitanu State University of Medicine and Pharmacy
2 shared publications - Iurie Dondiuc
Faculty of Medicine, Nicolae Testemitanu University of Medicine and Pharmacy, 2004 Chisinau, Moldova
2 shared publications - Liliana Profire
”Nicolae Testemitanu” State University of Medicine and Pharmacy
2 shared publications - Natalia Corolcova
”Nicolae Testemitanu” State University of Medicine and Pharmacy
2 shared publications - Veronica Cotelea
”Nicolae Testemitanu” State University of Medicine and Pharmacy
2 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Asociatia de Biosiguranta si Biosecuritate din Republica Moldova in One Health & Risk Management
- Vol. 7 (4) , 73-82
Pregnant women’s criteria for selecting obstetric care providers
Introduction Recent health system reforms in the Republic of Moldova have given pregnant women greater choice in selecting a maternity facility for childbirth. This study aimed to examine women’s views on the selection of obstetric care providers, identify key decision-making criteria, and develop recommendations for targeted marketing strategies in maternity care. Materials and Methods A quantitative cross-sectional study was conducted among 533 pregnant women recruited using non-probability convenience sampling. A study-specific structured questionnaire was administered both online and in paper format through healthcare institutions. Statistical analyses were performed using SPSS and Microsoft Excel to identify and quantify the factors influencing the selection of obstetric care providers and maternity facilities. Results The choice of maternity facility was influenced by a combination of medical, socioeconomic, institutional, and individual factors. The criteria most frequently rated as highly important were the professional competence of medical staff (84.8%; 95% CI: 81.49–88.12), the availability of modern medical equipment (70.8%; 95% CI: 66.22–75.38), and adherence to appropriate hygiene standards in the maternity ward (64.0%; 95% CI: 58.91–69.09). Conclusions The choice of maternity facility is a complex decision-making process, shaped by careful evaluation of prior experiences, institutional reputation, the professionalism of medical personnel, available facilities and services, and access to up-to-date information.
- 27 October 2026
- Published by Asociatia de Biosiguranta si Biosecuritate din Republica Moldova in One Health & Risk Management
- Vol. 7 (4) , 73-82
Open AccessPregnant women’s criteria for selecting obstetric care providers
Introduction Recent health system reforms in the Republic of Moldova have given pregnant women greater choice in selecting a maternity facility for childbirth. This study aimed to examine women’s views on the selection of obstetric care providers, identify key decision-making criteria, and develop recommendations for targeted marketing strategies in maternity care. Materials and Methods A quantitative cross-sectional study was conducted among 533 pregnant women recruited using non-probability convenience sampling. A study-specific structured questionnaire was administered both online and in paper format through healthcare institutions. Statistical analyses were performed using SPSS and Microsoft Excel to identify and quantify the factors influencing the selection of obstetric care providers and maternity facilities. Results The choice of maternity facility was influenced by a combination of medical, socioeconomic, institutional, and individual factors. The criteria most frequently rated as highly important were the professional competence of medical staff (84.8%; 95% CI: 81.49–88.12), the availability of modern medical equipment (70.8%; 95% CI: 66.22–75.38), and adherence to appropriate hygiene standards in the maternity ward (64.0%; 95% CI: 58.91–69.09). Conclusions The choice of maternity facility is a complex decision-making process, shaped by careful evaluation of prior experiences, institutional reputation, the professionalism of medical personnel, available facilities and services, and access to up-to-date information.
- 1 November 2025
- Published by Editorial Office "Bulletin of the Academy of Sciences of Moldova. Medical Sciences"
- No. 2(82),p. 292-300
Venous thromboembolism in pregnancy: therapeutic options
Introduction. Venous thromboembolism is a rare but significant cause of maternal morbidity and mortality during pregnancy and postpartum, affecting 1 in 1,000-2,000 pregnancies. Despite advancements in the treatment of venous thromboembolism in the general population, its management during pregnancy remains a challenge due to therapeutic limitations and the risks associated with anticoagulants for both the mother and the fetus. Prevention and treatment predominantly rely on the use of unfractionated heparin or low-molecular-weight heparin, which, while effective, are associated with maternal and fetal risks such as thrombocytopenia, osteoporosis, and neonatal bleeding. Methods. The study included original articles from specialized journals such as PubMed, Cochrane Library, and Google Scholar, focusing on venous thromboembolism, deep vein thrombosis, and pulmonary embolism during pregnancy. Articles on superficial venous thrombosis, arterial thrombosis, and other uncommon locations were excluded. The search strategy used controlled terms and relevant keywords. Results. Venous thromboembolism is the leading cause of maternal mortality in developed countries, with a postpartum risk of pulmonary embolism up to 35 times higher than during the antepartum period. Pregnancy-specific hypercoagulability is influenced by physiological factors such as increased levels of fibrinogen and coagulation factors. Hemostatic changes, mechanical compression of pelvic veins, and venous stasis contribute to the predisposition for venous thromboembolism. Anticoagulant treatments such as low-molecular-weight heparin and unfractionated heparin are most commonly used, involving distinct therapeutic phases: initial, primary, and extended, each with specific objectives in preventing venous thromboembolism recurrence. Conclusions. Managing venous thromboembolism during pregnancy requires personalized approaches that balance the risks and benefits of anticoagulation. Improving treatment strategies depends on further research to evaluate the safety and efficacy of new anticoagulants, particularly during pregnancy and postpartum.
- 1 November 2025
- Published by Editorial Office "Bulletin of the Academy of Sciences of Moldova. Medical Sciences"
- No. 2(82),p. 292-300
Venous thromboembolism in pregnancy: therapeutic options
Introduction. Venous thromboembolism is a rare but significant cause of maternal morbidity and mortality during pregnancy and postpartum, affecting 1 in 1,000-2,000 pregnancies. Despite advancements in the treatment of venous thromboembolism in the general population, its management during pregnancy remains a challenge due to therapeutic limitations and the risks associated with anticoagulants for both the mother and the fetus. Prevention and treatment predominantly rely on the use of unfractionated heparin or low-molecular-weight heparin, which, while effective, are associated with maternal and fetal risks such as thrombocytopenia, osteoporosis, and neonatal bleeding. Methods. The study included original articles from specialized journals such as PubMed, Cochrane Library, and Google Scholar, focusing on venous thromboembolism, deep vein thrombosis, and pulmonary embolism during pregnancy. Articles on superficial venous thrombosis, arterial thrombosis, and other uncommon locations were excluded. The search strategy used controlled terms and relevant keywords. Results. Venous thromboembolism is the leading cause of maternal mortality in developed countries, with a postpartum risk of pulmonary embolism up to 35 times higher than during the antepartum period. Pregnancy-specific hypercoagulability is influenced by physiological factors such as increased levels of fibrinogen and coagulation factors. Hemostatic changes, mechanical compression of pelvic veins, and venous stasis contribute to the predisposition for venous thromboembolism. Anticoagulant treatments such as low-molecular-weight heparin and unfractionated heparin are most commonly used, involving distinct therapeutic phases: initial, primary, and extended, each with specific objectives in preventing venous thromboembolism recurrence. Conclusions. Managing venous thromboembolism during pregnancy requires personalized approaches that balance the risks and benefits of anticoagulation. Improving treatment strategies depends on further research to evaluate the safety and efficacy of new anticoagulants, particularly during pregnancy and postpartum.
- Open Access
- 21 October 2025
- Published by Clujul Medical in Medicine and Pharmacy Reports
- Vol. 99 (1) , 80-85
Severe postpartum sepsis secondary to a deep vaginal hematoma: clinical and therapeutic aspects
Introduction. Puerperal sepsis is still a life-threatening obstetric complication worldwide, even in settings with advanced medical resources. Clinical manifestations may be subtle and atypical during pregnancy and the puerperium, leading to delays in recognition and treatment. Multidrug-resistant organisms such as Stenotrophomonas maltophilia further complicate management, often requiring aggressive multidisciplinary approaches. Case presentation. We present a case of vaginal hematoma and peripartum infection with Stenotrophomonas maltophilia accompanied by multiple organ dysfunction syndrome. Conclusions. The presence of pelvic contusion leads to sepsis caused by multiple infections in the peripartum period and can significantly increase the incidence of diseases associated with bleeding, infection, surgery, and blood product transfusions. The clinical condition of the patient may be worsened in the presence of pre-existing conditions prior to pregnancy.
- 21 October 2025
- Published by Clujul Medical in Medicine and Pharmacy Reports
- Vol. 99 (1) , 80-85
Open AccessSevere postpartum sepsis secondary to a deep vaginal hematoma: clinical and therapeutic aspects
Introduction. Puerperal sepsis is still a life-threatening obstetric complication worldwide, even in settings with advanced medical resources. Clinical manifestations may be subtle and atypical during pregnancy and the puerperium, leading to delays in recognition and treatment. Multidrug-resistant organisms such as Stenotrophomonas maltophilia further complicate management, often requiring aggressive multidisciplinary approaches. Case presentation. We present a case of vaginal hematoma and peripartum infection with Stenotrophomonas maltophilia accompanied by multiple organ dysfunction syndrome. Conclusions. The presence of pelvic contusion leads to sepsis caused by multiple infections in the peripartum period and can significantly increase the incidence of diseases associated with bleeding, infection, surgery, and blood product transfusions. The clinical condition of the patient may be worsened in the presence of pre-existing conditions prior to pregnancy.
- 1 December 2023
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 66 (2) , 20-23
Are Lactoferrin and Interleukine-6 preterm birth participants?
Background: Preterm birth remains a leading obstetrical complication because of the incomplete understanding of its multifaceted etiology. It is known that immune alterations toward a proinflammatory profile are observed in women with preterm birth, but therapeutic interventions are still lacking because of scarcity of evidence in the integration of maternal and placental interrelated compartments. Objective: To investigate value of Lactoferrin (LF) and Interleukine-6 (IL-6) in the preterm labor. Material and methods: The study comprised 65 women with spontaneous preterm labor and 65 women with term labor. Maternal plasma concentrations of Lactoferrin and Interleukine-6 were detected by standard test system Aeskulisa Lactoferrin and Best-Vector A-8768 for Interleukine-6 Ref 3307 which (GmbH & Co, Germany) gave an analytical sensitive of 1.0 U/ml for Lactoferrin and 0.131 pg/ml for Interleukine-6. Results: Plasma levels of Lactoferrin in women with preterm labor were lower (μmedian = 0.90 U/ml) (p<0.001) than in the control subjects (μmedian = 40.68 U/ml). Plasma levels of Interleukine-6 in the plasma in women with preterm were predictably higher (μmedian = 51.90 pg/ml) than that in the control subjects with term delivery (μmedian = 21.51 pg/ml) (p<0.001). Conclusions: The study findings suggest that plasma levels of Lactoferrin and Interleukine-6 in women with preterm labor may be considered as a promising early biomarker for preterm labor.
- 1 December 2023
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 66 (2) , 20-23
Are Lactoferrin and Interleukine-6 preterm birth participants?
Background: Preterm birth remains a leading obstetrical complication because of the incomplete understanding of its multifaceted etiology. It is known that immune alterations toward a proinflammatory profile are observed in women with preterm birth, but therapeutic interventions are still lacking because of scarcity of evidence in the integration of maternal and placental interrelated compartments. Objective: To investigate value of Lactoferrin (LF) and Interleukine-6 (IL-6) in the preterm labor. Material and methods: The study comprised 65 women with spontaneous preterm labor and 65 women with term labor. Maternal plasma concentrations of Lactoferrin and Interleukine-6 were detected by standard test system Aeskulisa Lactoferrin and Best-Vector A-8768 for Interleukine-6 Ref 3307 which (GmbH & Co, Germany) gave an analytical sensitive of 1.0 U/ml for Lactoferrin and 0.131 pg/ml for Interleukine-6. Results: Plasma levels of Lactoferrin in women with preterm labor were lower (μmedian = 0.90 U/ml) (p<0.001) than in the control subjects (μmedian = 40.68 U/ml). Plasma levels of Interleukine-6 in the plasma in women with preterm were predictably higher (μmedian = 51.90 pg/ml) than that in the control subjects with term delivery (μmedian = 21.51 pg/ml) (p<0.001). Conclusions: The study findings suggest that plasma levels of Lactoferrin and Interleukine-6 in women with preterm labor may be considered as a promising early biomarker for preterm labor.